PT-141 (Bremelanotide): Melanocortin Receptor Research
Apr 11, 2026·4 min read
Background
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). The compound was developed from the earlier linear peptide Melanotan II through cyclization and truncation to improve receptor selectivity and metabolic stability. PT-141 acts as a non-selective agonist at melanocortin receptors, with research primarily focused on its interactions with the MC3R and MC4R subtypes expressed in the central nervous system.
The compound is distinguished from peripheral vasodilators by its central mechanism of action. Published research indicates that PT-141's effects are mediated through hypothalamic and limbic melanocortin receptor activation rather than through peripheral vascular mechanisms. This mechanistic distinction has been documented through comparative pharmacological studies and receptor binding assays.
Clinical Pharmacology Studies
The clinical pharmacology of PT-141 was characterized by Rosen et al. (2004), published in the International Journal of Impotence Research. This study evaluated the safety, pharmacokinetics, and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to sildenafil. Doses ranging from 0.3 to 10 mg were administered, and the researchers reported a statistically significant erectile response at doses greater than 1.0 mg as measured by RigiScan monitoring.
The pharmacokinetic profile demonstrated rapid absorption following subcutaneous administration, with peak plasma concentrations reached within approximately 30 minutes. The compound's effects were temporally correlated with plasma levels, supporting a direct pharmacological relationship.
Melanocortin Receptor Characterization
Molinoff et al. (2003), publishing in the Annals of the New York Academy of Sciences, provided a detailed characterization of PT-141 as a melanocortin receptor agonist. The publication reviewed receptor binding data across the five known melanocortin receptor subtypes (MC1R through MC5R) and documented the compound's affinity profile. The MC3R and MC4R subtypes, which are predominantly expressed in the hypothalamus and limbic structures, were identified as the primary targets of pharmacological interest.
In vitro receptor binding assays demonstrated that PT-141 activates melanocortin receptors in a concentration-dependent manner, as measured by intracellular cAMP accumulation in cells expressing individual receptor subtypes.
Phase III Clinical Trial Data
PT-141 underwent Phase III clinical evaluation in a program that led to regulatory approval. Kingsberg et al. (2019), publishing in Obstetrics & Gynecology, reported the results of two randomized, double-blind, placebo-controlled trials (RECONNECT studies) enrolling over 1,200 premenopausal women. The studies evaluated subcutaneous self-administration of bremelanotide 1.75 mg on an as-needed basis.
The trials reported statistically significant improvements in the primary endpoint compared with placebo. The most commonly reported adverse event was nausea, which occurred in approximately 40% of treated subjects versus 1.3% in the placebo group. Transient increases in blood pressure were also documented, consistent with earlier phase studies.
The compound received regulatory approval from the U.S. Food and Drug Administration in June 2019 under the brand name Vyleesi.
Laboratory Handling Notes
PT-141 is supplied as a lyophilized powder and should be stored at -20°C in a desiccated environment. Reconstitution should be performed in sterile bacteriostatic water. The cyclic peptide structure confers greater stability compared to linear melanocortin analogs.
All findings discussed in this article are derived from peer-reviewed clinical and preclinical investigations. This compound is intended for research applications only.
References
- Molinoff, P.B., et al. "PT-141: a melanocortin agonist for the treatment of sexual dysfunction." Annals of the New York Academy of Sciences 994 (2003): 96-102.
- Rosen, R.C., et al. "Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra." International Journal of Impotence Research 16.2 (2004): 135-142.
- Diamond, L.E., et al. "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction." International Journal of Impotence Research 16.1 (2004): 51-59.
- Kingsberg, S.A., et al. "Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials." Obstetrics & Gynecology 134.5 (2019): 899-908.
